This discrepancy between the current state of mechanistic knowledge (represented in the DEABM) and the recognized real-world preponderance of ER+ cancers led us to posit that a key functional gap in the current state of knowledge concerning breast tumorigenesis was in accounting for the control structure governing the proliferative potential of ER+ cells. The gene discussed is ESR1; the disease is cancer.